Anti-EGFR Therapy With IMRT Concurrent Chemoradiotherapy in Locally Advanced OPC Resistant to Induction Chemotherapy

NCT04508829 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

52

Enrollment

OTHER

Sponsor class

Conditions

Oropharyngeal Carcinoma

Interventions

DRUG: Anti-EGFR monoclonal antibody

Sponsor

Fudan University